Flovent Hfa is owned by Glaxo Grp Ltd.
Flovent Hfa contains Fluticasone Propionate.
Flovent Hfa has a total of 4 drug patents out of which 0 drug patents have expired.
Flovent Hfa was authorised for market use on 14 May, 2004.
Flovent Hfa is available in aerosol, metered;inhalation dosage forms.
The generics of Flovent Hfa are possible to be released after 26 August, 2026.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7832351 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jun, 2023
(2 months from now) | |
US7832351
(Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Dec, 2023
(8 months from now) | |
US7500444 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Feb, 2026
(2 years from now) | |
US7500444
(Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Aug, 2026
(3 years from now) |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 14 May, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
3
European Union
2
Portugal
2
United Kingdom
2
Hong Kong
2
United States
2
Denmark
2
Spain
2
Japan
2
China
2
Cyprus
1
Germany
1
Austria
1
Australia
1
Brazil
1
Canada
1
Mexico
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic